Citations

Mayo Clinic

Showing 10 of 108572 citations.

Clinicopathologic features of a novel star-shaped transactive response DNA-binding protein 43 (TDP-43) pathology in the oldest old
Carlos, Arenn F. , Sekiya, Hiroaki , Gatto, Rodolfo G. , Casey, Monica Castanedes, Pham, Nha Trang Thu, Sintini, Irene , Jack, Clifford R. , Lowe, Val J. , Whitwell, Jennifer L. , Petrucelli, Leonard , Reichard, R. Ross , Petersen, Ronald C. , Josephs, Keith A. , Josephs, Keith A , Jack, Clifford R , Whitwell, Jennifer L , Carlos, Arenn F , Sekiya, Hiroaki , Koga, Shunsuke , Machulda, Mary M. , Dickson, Dennis W.

Journal of Neuropathology & Experimental Neurology | December 12, 2023 | Volume: 83 | Issue: 1 | Pages: 36-52

10.1093/jnen/nlad105 | PMID 38086178 Get It

Abstract Transactive response DNA-binding protein 43 (TDP-43) pathology is categorized as type A-E in frontotemporal lobar degeneration and as type α-β in Alzheimer disease (AD) based on inclusion type. We screened amygdala slides of 131 cases with varying ages at death, clinical/neuroimaging findings, and AD neuropathologic changes for TDP-43 pathology using anti-phospho-TDP-43 antibodies. Seven cases (5%) only showed atypical TDP-43 inclusions that could not be typed. Immunohistochemistry and immunofluorescence assessed the atypical star-shaped TDP-43 pathology including its distribution, species, cellular localization, and colocalization with tau. All 7 had died at an extremely old age (median: 100 years [IQR: 94–101]) from nonneurological causes and none had dementia (4 cognitively unimpaired, 3 with amnestic mild cognitive impairment). Neuroimaging showed mild medial temporal involvement. Pathologically, the star-shaped TDP-43-positive inclusions were found in medial (subpial) amygdala and, occasionally, in basolateral regions. Hippocampus only showed TDP-43-positive neurites in the fimbria and subiculum while the frontal lobe was free of TDP-43 inclusions. The star-shaped inclusions were better detected with antibodies against N-terminal than C-terminal TDP-43. Double-labeling studies confirmed deposition of TDP-43 within astrocytes and colocalization with tau. We have identified a novel TDP-43 pathology with star-shaped morphology associated with superaging, with a homogeneous clinicopathologic picture, possibly representing a novel, true aging-related TDP-43 pathology.
A Comparative Study of Two Topical Treatments for Photoaging of the Hands
Wyles, Saranya P. , Jankov, Laura Eaton, Copeland, Karen , Bucky, Louis P., Paradise, Christopher R. , Behfar, Atta

Plastic & Reconstructive Surgery | December 12, 2023 | Volume: 154 | Issue: 5 | Pages: 978-984

10.1097/prs.0000000000011240 | PMID 38086019 Get It

Background: Multiple effective treatments exist for correction of skin photoaging. Topical L-ascorbic acid (vitamin C), a well-known antioxidant and topical human platelet extract (HPE), is a novel off-the-shelf cosmetic ingredient that has shown positive results in recent clinical studies. HPE is a leukocyte-depleted allogeneic product derived from United States–sourced, pooled, apheresed platelets produced with consistent batch quality, purity, and effect. The authors sought to characterize the effect of topical HPE (plated) intense serum (Rion Aesthetics) compared with vitamin C (C E Ferulic with 15% L-ascorbic acid; SkinCeuticals) in skin rejuvenation of dorsal hands after 12 to 26 weeks of twice-daily use. Methods: This prospective, longitudinal study sought to compare the effectiveness of 2 known treatments for skin rejuvenation. Evaluations at baseline and 6, 12, and 26 weeks included photographic documentation to assess common skin concerns related to aging. Results: For age-related skin appearance on the dorsal hands, topical HPE was noninferior to topical vitamin C for improvement in brown spot fractional area, wrinkle fractional area, and improvement in luminosity at 12 weeks after twice-daily topical use. Conclusions: HPE performed as well as vitamin C to rejuvenate the skin on the dorsal hands after 12 to 26 weeks of twice-daily topical use. Both topical serums may yield similar or superior results versus invasive procedures, such as intense pulsed light, in reducing brown spots on the dorsal hands. These topical products work equally well in both sexes. Skin improvements lasted through 6 months. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q)
Tefferi, Ayalew , Fleti, Farah, Ali, Najla H. Al, Al‐Kali, Aref , Begna, Kebede H. , Foran, James M. , Badar, Talha , Khera, Nandita , Shah, Meera , Hiwase, Devendra , Padron, Eric , Sallman, David A. , Pardanani, Animesh , Reichard, Kaaren K. , He, Rong , Gangat, Naseema , Chan, Onyee , Al-Kali, Aref , Foran, James M , Badar, Talha , Shah, Mithun V , Hiwase, Devendra , Sallman, David A , Pardanani, Animesh , Arber, Daniel A , He, Rong , Gangat, Naseema , Komrokji, Rami S , Arber, Daniel A. , Orazi, Attilio , Ketterling, Rhett P. , Komrokji, Rami S.

British Journal of Haematology | December 12, 2023 | Volume: 204 | Issue: 4 | Pages: 1243-1248

10.1111/bjh.19247 | PMID 38083865 Get It

SummaryAmong 210 patients with myelodysplastic syndromes (MDSs) with del(5q), molecular information was available at diagnosis or at least 3 months before leukaemic transformation in 146 cases. Multivariate analysis identified therapy‐related setting (p = 0.02; HR 2.3) and TP53 variant allele frequency (VAF) ≥22% (p < 0.01; HR 2.8), but not SF3B1 mutation (p = 0.65), as independent risk factors for survival. Median survival was 11.7 versus 4 years (5/10‐year survival 73%/52% vs. 42%/14%) in the absence (N = 112) versus presence (N = 34) of ≥1 risk factors; leukaemia‐free survival was affected by TP53 VAF ≥22% (p < 0.01). Such information might inform treatment decision‐making in MDS‐del(5q) regarding allogeneic stem cell transplant.
Update on guidelines and recommendations for enhanced recovery after thoracic surgery
Cohen, Joshua , Smith, Bradford B., Teeter, Emily G. , Cohen, Joshua B., Smith, Bradford B.

Current Opinion in Anaesthesiology | December 12, 2023 | Volume: 37 | Issue: 1 | Pages: 58-63

10.1097/aco.0000000000001328 | PMID 38085879 Get It

Purpose of review Enhanced recovery after thoracic surgery (ERATS) has continued its growth in popularity over the past few years, and evidence for its utility is catching up to other specialties. This review will present and examine some of that accumulated evidence since guidelines sponsored by the Enhanced Recovery after Surgery (ERAS) Society and the European Society of Thoracic Surgeons (ESTS) were first published in 2019. Recent findings The ERAS/ESTS guidelines published in 2019 have not been updated, but new studies have been done and new data has been published regarding some of the individual components of the guidelines as they relate to thoracic and lung resection surgery. While there is still not a consensus on many of these issues, the volume of available evidence is becoming more robust, some of which will be incorporated into this review. Summary The continued accumulation of data and evidence for the benefits of enhanced recovery techniques in thoracic and lung resection surgery will provide the thoracic anesthesiologist with guidance on how to best care for these patients before, during, and after surgery. The data from these studies will also help to elucidate which components of ERAS protocols are the most beneficial, and which components perhaps do not provide as much benefit as previously thought.
From pain to gain: Leveraging acetaminophen in hepatocyte transplantation for phenylketonuria
Schulze, Ryan J. , Nyberg, Scott L. , Strom, Stephen C , Nyberg, Scott L

Hepatology | December 12, 2023 | Volume: 79 | Issue: 5 | Pages: 973-975

10.1097/hep.0000000000000713 | PMID 38085850 Get It

Current Topological and Machine Learning Applications for Bias Detection in Text
Farrelly, Colleen , Singh, Yashbir , Carlsson, Gunnar , Doretto, Gianfranco , Atalls, Shadi, Singh, Yashbir , Hathaway, Quincy A , Choudhary, Ashok, Paul, Rahul , Himeur, Yassine , Mansoor, Wathiq

2023 6th International Conference on Signal Processing and Information Security (ICSPIS) | December 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: 190-195

10.1109/icspis60075.2023.10343824 Get It

Natural History of Serviceable Hearing During Active Surveillance of Nongrowing Sporadic Vestibular Schwannoma Supports Consideration of Initial Wait-and-Scan Management
Khandalavala, Karl R. , Marinelli, John P. , Lohse, Christine M. , Daher, Ghazal S. , Kocharyan, Arminé , Neff, Brian A., Driscoll, Colin L. W., Celda, María Peris, Link, Michael J. , Carlson, Matthew L. , Gompel, Jamie J. Van

Otology & Neurotology | December 12, 2023 | Volume: 45 | Issue: 1 | Pages: e42-e48

10.1097/mao.0000000000004051 | PMID 38085766 Get It

Objective The treatment paradigm of vestibular schwannoma (VS) focuses on preservation of neurologic function, with small tumors increasingly managed with active surveillance. Often, tumor size and hearing outcomes are poorly correlated. The aim of the current work was to describe the natural history of hearing among patients with nongrowing VS during observational management. Study Design Historical cohort study. Patients Adults with sporadic VS. Intervention Wait-and-scan management. Main Outcome Measure Maintenance of serviceable hearing (SH) after diagnosis. Results Among 228 patients with nongrowing VS, 157 patients had SH at diagnosis. Rates of maintaining SH (95% CI; number still at risk) at 1, 3, and 5 years after diagnosis were 94% (89–98; 118), 81% (74–89; 65), and 78% (71–87; 42), respectively. Poorer hearing at diagnosis (hazard ratio [HR] per 10 dB hearing level increase in pure-tone average of 2.51, p < 0.001; HR per 10% decrease in word recognition score of 1.70, p = 0.001) was associated with increased likelihood of developing non-SH during observation. When controlling for baseline hearing status, tumors measuring 5 mm or greater in the internal auditory canal or with cerebellopontine angle extension were associated with significantly increased risk of developing non-SH (HR, 4.87; p = 0.03). At 5 years after diagnosis, 95% of patients with nongrowing intracanalicular VS measuring less than 5 mm maintained SH. Conclusions Hearing worsens during periods of nongrowth in sporadic VS. Patients with small (<5 mm) intracanalicular tumors demonstrate robust maintenance of SH over time, reinforcing the consideration of initial observation in this patient subset.
Dynamics of Serologic Change to Gluten in Celiac Disease Patients
Syage, Jack A. , Ramos, Ana Pilar , Loskutov, Vasiliy, Norum, Anna, Bledsoe, Adam C. , Choung, Rok Seon , Dickason, Matthew A., Sealey‐Voyksner, Jennifer A., Syage, Jack , Bledsoe, Adam, Choung, Rok Seon , Ramos, Ana, Murray, Joseph A.

Nutrients | December 12, 2023 | Volume: 15 | Issue: 24 | Pages: 5083

10.3390/nu15245083 | PMID 38140342 Get It

Serologic measures of tissue transglutaminase (tTG) immunoglobulin A (IgA) and deamidated gliadin peptide (DGP) IgA and immunoglobulin G (IgG) are hallmark tests utilized when diagnosing individuals for celiac disease (CeD) and for monitoring adherence to a gluten-free diet (GFD), currently the only available treatment for CeD. We address two issues in this study: (i) the relapse to seropositivity for CeD patients who resume a gluten containing diet and (ii) the correlation between two different tTG-IgA assays near the upper limit of normal (ULN) designated thresholds. Regarding the first issue, often a suspected CeD individual is put back on a gluten diet to return to their serologic levels. However, we show it requires a substantial amount of gluten for serology to return to a positive level. For example, in one study of 22 patients treated with placebo and taking 84 g of gluten over 6 weeks, only two converted from seronegative to seropositive for tTG-IgA. Regarding the second topic, we compare the relationship for different serologic assays, namely tTG-IgA AB (recombinant, ULN = 4 units/mL) vs. tTG-IgA (non-recombinant, ULN = 20 units). There is a strong correlation between both measurements as evidenced by a Pearson coefficient of R = 0.8584; however, we observed that the cross-correlation in terms of sensitivity and specificity improved substantially by using an ULN value of three instead of four for the tTG-IgA AB (recombinant) assay. This result suggests that assay thresholds used for initial diagnosis in patients who have not yet started a GFD may need to be adjusted for monitoring and in the setting of a diagnostic gluten challenge.
CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon
Zhu, Yan , Zhang, Dengyong , Jung, Young‐Ho , Chagani, Sharmeen , Benjamin, Sarah , Copland, John A. , Lorenzi, Philip L. , Javle, Milind , Kwong, Lawrence N. , Shukla, Pooja , Malgulwar, Prit Benny , Colic, Medina , Benjamin, Sarah, Tan, Lin , Huse, Jason T. , Roszik, Jason , Hart, Traver

JCI Insight | December 12, 2023 | Volume: 9 | Issue: 2 | Pages: No page available

10.1172/jci.insight.174220 | PMID 38060314 Get It

Patients with cholangiocarcinoma have poor clinical outcomes due to late diagnoses, poor prognoses, and limited treatment strategies. To identify drug combinations for this disease, we have conducted a genome-wide CRISPR screen anchored on the bromodomain and extraterminal domain (BET) PROTAC degrader ARV825, from which we identified anticancer synergy when combined with genetic ablation of members of the mTOR pathway. This combination effect was validated using multiple pharmacological BET and mTOR inhibitors, accompanied by increased levels of apoptosis and cell cycle arrest. In a xenograft model, combined BET degradation and mTOR inhibition induced tumor regression. Mechanistically, the 2 inhibitor classes converged on H3K27ac-marked epigenetic suppression of the serine glycine one carbon (SGOC) metabolism pathway, including the key enzymes PHGDH and PSAT1. Knockdown of PSAT1 was sufficient to replicate synergy with single-agent inhibition of either BET or mTOR. Our results tie together epigenetic regulation, metabolism, and apoptosis induction as key therapeutic targets for further exploration in this underserved disease.